eGFR-Average is the mean of creatinine-based and cystatin-C-based estimated glomerular filtration rate (eGFR), expressed in mL/min/1.73m². This combined estimate correlates better with measured kidney function than either method alone, making it the preferred approach in Swedish clinical practice. It represents your kidneys' ability to filter waste, a crucial marker of renal health and overall longevity.
This is a derived biomarker — calculated from directly measured values (serum creatinine and cystatin C).
Analyzed in accredited Swedish clinical laboratories (ISO 15189). Used to support clinician-directed evaluation and monitoring. Not a stand-alone diagnosis.
Concerned about your kidney health or managing a family history of kidney disease? eGFR-Average is the single best non-invasive screen of kidney function. Unlike single-method estimates, the averaged approach catches earlier decline and is more reliable across different body types and ages. If you have hypertension, diabetes, or a personal or family history of chronic kidney disease (CKD), testing eGFR-Average should be routine.
Even if you feel well and have no obvious risk factors, eGFR declines gradually with age — on average about 1 mL/min/year after age 40. Knowing your baseline and trend is essential for longevity planning. Loovi's annual tracking lets you spot decline early, when intervention is most effective.
Captures true kidney function. By averaging creatinine-based and cystatin-C-based estimates, eGFR-Average is less vulnerable to individual confounders (muscle mass, diet, liver function) and correlates more closely with directly measured kidney function (iohexol clearance).
Identifies early decline. Slopes of eGFR over time matter more than a single snapshot — eGFR-Average trend detection helps catch functional decline years before symptoms appear.
Guides CKD staging. eGFR is the backbone of chronic kidney disease classification (G1 through G5), which determines when interventions are needed and how aggressively.
Refines cardiovascular risk. Kidney function predicts cardiovascular events independent of traditional risk factors. Even mild eGFR decline correlates with higher mortality.
Contextualizes other markers. eGFR-Average ties together interpretation of creatinine, cystatin-c, urea, and electrolytes — without knowing kidney function, those markers are ambiguous.
Detects medication effects. Many drugs (ACE inhibitors, ARBs, NSAIDs, diuretics, statins) affect kidney function; eGFR-Average tracks these shifts with less noise.
The filtration challenge. Your kidneys filter waste products (urea, creatinine, phosphate) from blood while retaining useful molecules (glucose, amino acids, water). The glomeruli — microscopic filtering units — handle this load. Estimating how fast they filter (glomerular filtration rate, or GFR) is central to kidney health assessment. Measured GFR requires invasive testing (iohexol clearance, a radioisotope procedure), so clinicians estimate it from serum markers.
Why two equations? Creatinine-based eGFR relies on muscle breakdown product serum creatinine — straightforward but biased by muscle mass, diet, liver function, and age. Cystatin-C-based eGFR uses a different endogenous marker (a protein freely filtered by glomeruli) and is less affected by muscle. Each method has blind spots. Swedish clinical practice and the 2021 CKD-EPI guideline (the race-free standard now adopted across Europe) recommend averaging the two when estimates diverge significantly — the combined value correlates best with true kidney function.
The averaging principle. When creatinine-based eGFR and cystatin-C-based eGFR differ by >15%, their mean is more reliable than either estimate alone. This is especially valuable in people with unusual muscle mass, malnutrition, liver disease, or sarcopenia, where one method alone can be misleading.
Predicts overall mortality independent of age. eGFR decline tracks ageing better than chronological age alone. Individuals with slower decline over 5–10 years have longer lifespans and lower disease burden — it's a proxy for whole-body ageing rate.
Identifies hidden kidney burden. Many people with early CKD (stages G2–G3a) are asymptomatic; eGFR-Average catches decline before complications (anemia, bone disease, hypertension, cardiovascular events) emerge.
Guides preventive intervention timing. The sooner you know your baseline and trend, the earlier you can address modifiable drivers (hypertension, glycemic control, medication side effects, diet). Early intervention slows decline more powerfully than late intervention.
Contextualizes treatment thresholds. Medications (statins, SGLT2 inhibitors, GLP-1 agonists, ACE inhibitors) have kidney-function-dependent efficacy and safety — eGFR-Average determines which drugs are options and at what doses.
G1 (Normal or High): >90 mL/min/1.73m² — standard healthy kidney function, though >120 may reflect younger age or hyperfiltration.
G2 (Mildly Reduced): 60–89 mL/min/1.73m² — technically normal by standard definitions, but eGFR-Average <75 in someone age >50 warrants closer monitoring.
G3a (Mild-to-Moderate Reduction): 45–59 mL/min/1.73m² — early CKD; progression risk rises, and some medications require dose adjustment.
G3b (Moderate Reduction): 30–44 mL/min/1.73m² — significant CKD; close monitoring and aggressive risk-factor control are essential.
G4 (Severe Reduction): 15–29 mL/min/1.73m² — advanced CKD; specialist nephrology input recommended.
G5 (Kidney Failure): <15 mL/min/1.73m² — renal replacement therapy (dialysis or transplant) typically needed.
In Loovi's longevity context, the key insight is not hitting a single threshold but tracking rate of decline. After age 40, eGFR normally declines ~1 mL/min/year. Slower decline signals healthy ageing; faster decline (2–3+ mL/min/year) signals accelerated kidney ageing and warrants investigation.
High eGFR-Average (>90 mL/min/1.73m²). Normal kidney function; no kidney disease. Very high values (>120) are common in younger adults and those with lean muscle mass — not a problem unless accompanied by proteinuria or a rapid falling trend.
Optimal eGFR-Average (60–90 mL/min/1.73m²). Fully functional kidneys. G2 stage does not define CKD unless albuminuria is present. However, if you are over age 50 and eGFR-Average is trending downward faster than 1 mL/min/year, investigation is warranted — this may signal early vascular disease, uncontrolled hypertension, or metabolic stress.
Mildly reduced eGFR-Average (45–59 mL/min/1.73m²). G3a CKD — mild but real functional loss. Risk of progression increases, especially if driven by modifiable factors (hypertension, diabetes, NSAID use). Blood pressure targets tighten, and certain medications may need dose adjustment. Cystatin-C and creatinine-based estimates should be checked individually — if they diverge widely, repeat testing confirms the averaging is reliable.
Moderately to severely reduced eGFR-Average (<45 mL/min/1.73m²). G3b or worse — significant CKD requiring specialist input. Risk of anaemia, bone disease, electrolyte shifts, and cardiovascular complications rises steeply. Medication choices narrow; some agents become contraindicated. Referral to nephrology is typically indicated.
Factors that influence eGFR-Average. Acute illness (infection, dehydration, contrast agent exposure) can temporarily drop eGFR. Creatinine rises with intense muscle damage (rhabdomyolysis, heavy eccentric training, crush injury). Cystatin-C is affected by corticosteroid use, thyroid status, and inflammation. Pregnancy lowers both markers (eGFR rises), so interpretation in pregnant individuals differs. For stable assessment, avoid testing within 48 hours of intense exercise, during acute illness, or immediately after medication changes.
Hypertension. Elevated blood pressure damages the glomerular capillaries over years, reducing filtration. This is the single largest preventable driver of CKD globally. Control of blood pressure (typically <120/80 mmHg in CKD) is the cornerstone of slowing decline.
Diabetes (Type 1 and Type 2). High blood glucose damages the glomerular basement membrane through glycation and inflammation. Tight glycemic control and early SGLT2-inhibitor or GLP-1-agonist therapy (which have renoprotective effects beyond glucose control) slow decline significantly.
Chronic NSAID or ifosfamide use. NSAIDs reduce renal blood flow and can precipitate acute kidney injury or accelerate decline in people with baseline CKD or dehydration. Long-term use compounds this risk.
Age and inherited genetic factors. eGFR naturally declines with age; rate of decline varies genetically. Some individuals have naturally lower eGFR without disease (familial hypofiltration). APOL1 gene variants (common in people of African ancestry) increase CKD risk significantly.
Smoking, obesity, and metabolic dysfunction. These drive systemic inflammation and endothelial damage, accelerating glomerular loss. Metabolic syndrome clusters with CKD risk.
Blood pressure control. The most powerful lever. Reducing systolic blood pressure by 10–15 mmHg slows eGFR decline by ~30%. ACE inhibitors and ARBs are first-line, not just for blood pressure but also for their direct renoprotective effects (they dilate the efferent arteriole, reducing glomerular pressure).
Glycemic control. In diabetes, tight HbA1c control (below 7% in most, individualized lower in some) combined with SGLT2 inhibitors (which reduce intraglomerular pressure and promote natriuresis) or GLP-1 agonists (which improve insulin sensitivity and promote weight loss) are synergistic.
Dietary sodium and protein. High sodium intake raises blood pressure and glomerular hyperfiltration. Moderate protein restriction (1–1.2 g/kg/day rather than 1.6–2.0 g/kg/day) reduces glomerular workload without harming muscle if training is adequate. Plant-based proteins are modestly more renoprotective than animal proteins.
Weight loss if overweight, metabolic health optimization. Reducing insulin resistance and systemic inflammation through sustained moderate weight loss, regular aerobic training, and strength work protects the kidneys indirectly by improving vascular and metabolic health across the board.
Avoid nephrotoxins. Limit NSAIDs; if pain management is needed, paracetamol or topical agents are safer. Be cautious with contrast agents if eGFR is <30. Avoid herbal remedies with aristolochic acid (rare but can cause rapid CKD). Alcohol moderation also protects.
The right intervention depends on the driver of your decline — hypertension-driven CKD responds most to blood pressure lowering; diabetes-driven CKD benefits most from tight glucose control plus SGLT2 inhibitors; primary glomerulonephritis requires immunosuppression. A Loovi longevity doctor will map your full biomarker profile and medical history to prioritize these levers.
eGFR-Average is a single number describing filtration rate — it does not tell you why function is declining or what else is going wrong. Creatinine, cystatin-c, and urea all provide additional context: wide divergence between creatinine-based and cystatin-C-based eGFR suggests confounding (unusual muscle mass, malnutrition, liver disease). Urea that is disproportionately high relative to creatinine may suggest dehydration or high protein catabolism. Proteinuria (measured separately via urine albumin-to-creatinine ratio, UACR) is a crucial risk modifier — albuminuria at any eGFR level signals glomerular damage and multiplies CKD progression risk.
Beyond kidney markers, contextualizing eGFR-Average alongside blood pressure, HbA1c, and lipid markers (especially Lp(a) and hs-CRP) is essential. Kidney disease accelerates cardiovascular disease and vice versa. Electrolytes (potassium, sodium, phosphate, calcium), haemoglobin, and bone markers become increasingly relevant as eGFR falls — ion handling breaks down and anaemia, bone disease, and mineral metabolism dysregulation emerge.
This is why Loovi tracks 120+ biomarkers annually. A longevity doctor maps your full biomarker profile to understand not just your kidney function, but the drivers of decline and your cardiovascular, metabolic, and bone health in light of renal status. A single eGFR-Average result, without trend, without context, and without a full picture, is clinically incomplete.
Yes. The Swedish Society of Nephrology and current KDIGO/CKD-EPI guidance recommend eGFR-Average (the mean of both equations) as the preferred estimate, especially when the two methods diverge by more than 15%. It is more accurate, less biased by body composition and diet, and correlates better with measured kidney function. If Loovi offers both, averaging is the gold standard.
Divergence signals a confounder affecting one method more than the other. High muscle mass and intense training elevate creatinine without reflecting true kidney decline; malnutrition, liver disease, or sarcopenia lower creatinine falsely. Cystatin-C can be affected by thyroid dysfunction, inflammation, or corticosteroid use. When estimates diverge >15%, the averaged value is more trustworthy. Recheck both; if discordance persists, urine creatinine clearance (24-hour collection) or direct imaging may clarify.
Normal decline is ~1 mL/min/year after age 40 in people without kidney disease. With CKD, decline typically accelerates to 2–5+ mL/min/year unless intervened. Reversibility depends on cause: acute kidney injury (from dehydration, contrast, medication) can fully recover if the insult is removed; chronic CKD from hypertension or diabetes can be slowed but not reversed, though aggressive treatment can bring decline back to a normal ~1 mL/min/year rate. Once glomeruli are scarred (end-stage), function cannot be restored without transplant.
Creatinine is always covered; cystatin-C testing is increasingly standard in Swedish healthcare but may require private or specialist ordering at some centres. Loovi includes both in its comprehensive annual panel and calculates eGFR-Average as part of the analysis.
ACE inhibitors and ARBs may cause a small initial dip in eGFR (10–15%) within weeks of starting — this is not kidney damage but rather a beneficial reduction in glomerular hyperfiltration pressure. Continue the drug unless eGFR drops >30% or falls below 30 mL/min, in which case renal specialist input is needed. SGLT2 inhibitors and GLP-1 agonists typically improve or stabilize eGFR over months. NSAIDs, diuretics, and contrast agents all carry kidney risk; discuss with a doctor before use if eGFR is <60.
Pregnancy increases glomerular filtration as a normal adaptation; eGFR rises 20–30% and creatinine and cystatin-C both fall. This is healthy, not disease. eGFR-Average testing is safe during pregnancy (it is not radiological or invasive), but interpretation differs — “normal” ranges shift upward, and a creatinine of 0.7 mmol/L (which looks normal postpartum) may indicate kidney dysfunction during pregnancy. Postpartum, eGFR returns to baseline within weeks.
By definition, you are in CKD stage G3a. However, “disease” requires additional evidence: albuminuria (UACR >30 mg/g), imaging abnormalities, or a rising trend. eGFR alone does not diagnose CKD without one of these factors. If eGFR is stable and you have no albuminuria, hypertension, or diabetes, CKD risk is lower. A Loovi consultation would evaluate your full picture — family history, medications, blood pressure, lipids, glucose control — to determine risk and intervention priorities.
Measured GFR (inulin clearance, iohexol, radioisotope methods) is the gold standard but invasive, expensive, and rarely used outside nephrology specialist settings. eGFR-Average by 2021 CKD-EPI is accurate enough for clinical decision-making in most cases. If eGFR-Average is borderline (e.g., 30–45) and diagnosis is critical (e.g., before transplant work-up or aggressive immunosuppression), measured GFR may be justified — discuss with a nephrologist.
